OneOme
OneOme was a Minneapolis-based pharmacogenomics company co-founded with Mayo Clinic that offered the RightMed Test, a 27-gene, 300-medication PGx panel, to health systems, payers, PBMs, employers, and pharmacies before ceasing operations in November 2025.
- Company typePrivate
- Founded2015
- HeadquartersMinneapolis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What OneOme does
OneOme was a Minneapolis-based pharmacogenomics (PGx) company co-founded with Mayo Clinic in 2014/2015 to translate genetic variation in drug response into routine clinical decision-making. Its flagship offering, the RightMed Test, used PCR-based analysis of patient DNA (from blood or cheek swab) to interrogate 27 genes and generate medication response insights across 300+ drugs, packaged within the broader RightMed Solution suite that included HIPAA-compliant Provider and Patient Portals, EHR integration and alerts, clinical consults, training, and the RightMed for Populations module targeting payers, PBMs, and employers.
The company commercialized through multiple parallel channels: direct enterprise sales to health systems, channel/reseller relationships (notably Alliance Healthcare Netherlands for Boots and Alphega Pharmacy retail distribution), payer/PBM/employer population health programs (Blue Care Network, Navitus), technology partnerships that embedded RightMed within medication decision support stacks (Tabula Rasa HealthCare, Family Care Path), and direct patient self-pay kits. Revenue mechanics combined one-time test fees billed to insurance (as an out-of-network lab), institutional billing under multi-year contracts, a $349 self-pay price, and a Financial Assistance Program capping out-of-pocket cost at $199 for qualifying patients.
OneOme held a CLIA-certified, CAP-accredited clinical laboratory at its Minneapolis headquarters and was licensed across all U.S. states including high-barrier jurisdictions (New York, California). Backed by early-stage venture firm Invenshure, LLC and Mayo Clinic, the company disclosed approximately $6.39M in funding across three rounds (2015-2017). OneOme ceased PGx testing operations in November 2025 due to financial challenges, and Tempus AI subsequently acquired its pharmacogenetics assets.
OneOme firmographics
Firmographics- Name
- OneOme
- Legal name
- OneOme, LLC
- Website
- https://oneome.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- OneOme was a Minneapolis-based pharmacogenomics company co-founded with Mayo Clinic that offered the RightMed Test, a 27-gene, 300-medication PGx panel, to health systems, payers, PBMs, employers, and pharmacies before ceasing operations in November 2025.
- Ownership category
- akta.pro rank
OneOme industry classification
Industry- Product category
- Pharmacogenomic Laboratory Testing Services
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pharmacogenomics (PGx) Decision Support (HLAAANAB)
- akta.pro secondary industry
- Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)
Keywords
Where OneOme is headquartered
LocationHeadquarters
- HQ city
- Minneapolis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
OneOme business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- RightMed Test Services: One-time pharmacogenomic laboratory testing services where healthcare providers order tests for patients. Revenue generated from test processing fees billed to insurance, patients directly (self-pay), or institutional accounts. The test analyzes 27 genes to provide medication optimization recommendations.
- Insurance Billing: Laboratory billing services submitted to insurance companies on behalf of patients. OneOme is an out-of-network laboratory with most insurance companies. Patients may be responsible for deductibles, coinsurance, and copayments depending on their insurance coverage.
- Patient Self-Pay: Direct patient payment option for those without insurance coverage or who choose not to bill insurance. Currently priced at $349 for self-pay patients.
- Financial Assistance Program: Needs-based assistance program providing access to the RightMed Test for patients who qualify based on household income limits. Qualifying patients have a maximum out-of-pocket cost of $199.
- Institutional/Enterprise Billing: Billing arrangements for health systems, payers, and employer groups implementing population-level PGx programs. Includes check, credit card, or wire transfer payment options.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Self-Pay Price |
| One time/ perpetual license | Pay-as-you-go | Financial Assistance Program (FAP) Price |
| Other | Pay-as-you-go | Insurance Billing |
| Other | Multi-year contract | Institutional Billing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
OneOme product offering
Product offeringCore offering
OneOme provides the RightMed Test, a pharmacogenomic (PGx) test that analyzes 27 genes covering 300+ medications using PCR technology on DNA from cheek swab or blood samples. The RightMed Solution bundles the test with HIPAA-compliant Provider and Patient Portals, clinical consults, EHR integration, and population health modules for health systems, payers, and providers. Tests must be ordered by licensed healthcare providers, and the company operates its own CLIA-certified, CAP-accredited clinical laboratory in Minneapolis.
Product overview
OneOme offers the RightMed Solution as its primary product portfolio, centered on the RightMed Test—a pharmacogenomic test analyzing 27 genes for 300+ medications. The RightMed Solution includes complementary clinical consults, Provider and Patient Portals, EHR integration tools, and training programs. For population health management, OneOme offers the RightMed for Populations module targeting payers and employers. The company provides end-to-end pharmacogenomic testing services from sample collection (cheek swab or blood) through interpretation and clinical support.
Differentiator
Problem solved
Functional benefit
Brands
- RightMed: OneOme's flagship pharmacogenomic test and solution platform, including the RightMed Test and RightMed for Populations program.
Products and services
- RightMed Test A pharmacogenomic laboratory test that analyzes 27 genes from a patient's DNA (via cheek swab or blood) to predict response to 300+ medications. Ordered by licensed healthcare providers to inform medication selection and dosing for individual patients.
- RightMed Solution A bundled suite of products and services for pharmacogenomics, including the RightMed Test, HIPAA-compliant portals, complimentary clinical consults with expert clinicians, training and education programs, and population health capabilities, tailored for payers, healthcare organizations, providers, and patients.
- RightMed for Populations A population health module designed for payers, PBMs, and employer groups to leverage pharmacogenomic testing across member populations, aiming to reduce total cost of care and improve patient outcomes through personalized medication decisions at scale.
- Provider and Patient Portals HIPAA-compliant web portals for healthcare providers to order tests, access results, and manage patient testing, and for patients to view their pharmacogenomic test reports and manage their testing experience.
Quantifiable outcome
- 1 in 3 patients had medication adjusted after PGx testing
- +1 more outcomes
Companies that use OneOme
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
OneOme technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
OneOme partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered major, significant and minor.
- Tabula Rasa HealthCaremajorPartnership to combine OneOme's RightMed Test and Interpretation Solutions with TRHC's MedWise medication decision support technology. The combination considers impact of external factors like other medications on gene expression, going beyond traditional single drug-gene pair assessment.
- Alliance Healthcare NetherlandsmajorExpanded agreement to provide RightMed Test to Alliance Healthcare employees (1,500+) and immediate family members as an employee benefit. This built on the earlier pilot program in Netherlands pharmacies.
- Family Care PathsignificantPartnership to add OneOme's RightMed Test to Family Care Path's MyLegacy genetic wellness application. Results are reviewed with individuals by Family Care Path genetic counselors through CarePathConnect video-based telegenetic service.
- Alliance Healthcare NetherlandsmajorPilot partnership with Alliance Healthcare Netherlands (Walgreens Boots Alliance subsidiary) to bring pharmacogenomic testing to selected Boots and Alphega Pharmacy locations throughout the Netherlands. The pilot evaluated feasibility of offering PGx testing in retail pharmacy settings.
- Blue Care NetworkmajorBlue Care Network (Blue Cross Blue Shield of Michigan's HMO) using OneOme's RightMed for Populations program for the Blue Cross Personalized Medicine program. Partnership aimed at reducing total cost of care and improving patient health outcomes.
- NavitusminorParmacy benefit management company using OneOme's PGx testing services and providing positive testimonial about quality and cost-effectiveness of the testing.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
OneOme competitors and assessment
Company assessmentBroad incumbents
- Tempus AI: AI-driven precision medicine platform that acquired OneOme's PGx assets in November 2025. Directly comparable as a molecular diagnostics and clinical decision-support company with overlapping technology stack and clinical customer base.
- Myriad Genetics: Established molecular diagnostics company offering genetic and pharmacogenomic tests across multiple therapeutic areas with broad payer relationships. Comparable as a larger incumbent operating in the same clinical genetic testing category.
- Invitae: Clinical genetic testing company serving clinicians, health systems, and biopharma across hereditary cancer, reproductive health, and pharmacogenomics — comparable as a comprehensive clinical lab with PGx offerings and EHR-integrated reporting.
- Quest Diagnostics: Largest US clinical lab offering a broad menu including pharmacogenomic panels with extensive in-network payer coverage — comparable as a competing PGx provider, though much larger scale and broader test menu than OneOme.
- Laboratory Corporation of America (LabCorp): Major US clinical laboratory network offering pharmacogenomic testing and comprehensive clinical diagnostics with broad payer contracts — comparable as a competing PGx lab with substantially greater scale and in-network coverage.
- Natera: Clinical genetic testing company spanning oncology, reproductive health, and organ transplant, with clinical decision support tooling and EHR integration — comparable as a specialty clinical lab with similar technology and provider workflow integrations.
- Genomic Health (Exact Sciences): Oncology-focused molecular diagnostics company acquired by Exact Sciences, offering genomic testing with clinical decision support for therapy selection — comparable as a precision medicine testing company using genetic insights to guide treatment decisions.
Direct peers
- Genomind: Pharmacogenomic testing company focused on mental health medication selection, offering PGx panels with clinical decision support to providers — directly comparable to OneOme's RightMed test and clinician workflow tools.
- Color Genomics: Clinical genetics company providing population-scale genetic testing including pharmacogenomics to health systems, employers, and payers, with integrated clinical decision support — closely aligned with OneOme's RightMed for Populations go-to-market.
Regional players
- Sonic Healthcare: International clinical laboratory and pathology operator with growing pharmacogenomic testing services, primarily serving Australia/Europe — comparable as a clinical lab offering PGx, though with different geographic footprint than OneOme's US/Netherlands presence.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
OneOme social profiles
Digital presenceOneOme compliance and trust
Trust signalCompliance6 records
OneOme financial estimates
Financial estimateRevenue estimate
Valuation estimate
OneOme leadership team
Management profileNumber of profiles
Profiles7 records
OneOme funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OneOme M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OneOme
What does OneOme do?
OneOme provides the RightMed Test, a pharmacogenomic (PGx) test that analyzes 27 genes covering 300+ medications using PCR technology on DNA from cheek swab or blood samples. The RightMed Solution bundles the test with HIPAA-compliant Provider and Patient Portals, clinical consults, EHR integration, and population health modules for health systems, payers, and providers. Tests must be ordered by licensed healthcare providers, and the company operates its own CLIA-certified, CAP-accredited clinical laboratory in Minneapolis.
Is OneOme a public or private company?
OneOme is a private company. It is classified as venture growth investor backed and is currently closed.
When was OneOme founded?
OneOme was founded in 2015. It employs 11 to 50 people.
Where is OneOme based?
OneOme is headquartered in Minneapolis, United States, in the North America region.
How does OneOme make money?
Five revenue lines are on record. RightMed Test Services are the primary driver. The others are insurance Billing, patient Self-Pay, financial Assistance Program and institutional/Enterprise Billing.
Who are OneOme's main competitors?
Broad incumbents on record are Tempus AI, Myriad Genetics, Invitae, Quest Diagnostics, Laboratory Corporation of America (LabCorp), Natera and Genomic Health (Exact Sciences). Direct peers are Genomind and Color Genomics. Sonic Healthcare is listed as a regional player.
Does OneOme have an API?
No public API is recorded for OneOme.
What industry is OneOme in?
OneOme's product category is Pharmacogenomic Laboratory Testing Services. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 62151 and its SIC code is 8071.